1	Detection of cross-reactive IgA against SARS-CoV-2
2	spike 1 subunit in saliva
3	
4	Keiichi Tsukinoki ^{1*} , Tatsuo Yamamoto ² , Keisuke Handa ³ , Mariko Iwamiya ⁴ ,
5	Juri Saruta ¹ , Satoshi Ino ⁵ , Takashi Sakurai ⁶
6	
7	¹ Department of Environmental Pathology, Graduate School of Dentistry, Kanagawa
8	Dental University, Yokosuka, Kanagawa, Japan.
9	² Department of Dental Sociology, Graduate School of Dentistry, Kanagawa Dental
10	University, Yokosuka, Kanagawa, Japan.
11	³ Department of Oral Biochemistry, Graduate School of Dentistry, Kanagawa Dental
12	University, Yokosuka, Kanagawa, Japan.
13	⁴ Department of Clinical Laboratory, Yokosuka, Kanagawa Dental University Hospital,
14	Yokosuka, Kanagawa, Japan.
15	⁵ Department of Minimal Intervention Prosthodontics, Graduate School of Dentistry,
16	Kanagawa Dental University, Yokohama, Kanagawa, Japan.
17	⁶ Department of Maxillofacial Radiology, Graduate School of Dentistry, Kanagawa Dental

¹⁸ University, Yokosuka, Kanagawa, Japan. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

19 *Corresponding author

- 20 E-mail: tsukinoki@kdu.ac.jp (KT)
- 21

22 Abstract

23Abundant secretory IgA (sIgA) in mucus, breast milk, and saliva provides immunity that 24prevents infection of mucosal surfaces. sIgA in pre-pandemic breast milk samples have 25been reported to cross-react with SARS-CoV-2, but whether it also occurs in saliva and, if so, whether it cross-reacts with SARS-CoV-2, has remained unknown. We aimed to 2627clarify whether sIgA in saliva cross-reacts with SARS-CoV-2 spike 1 subunit in 28individuals who have not been infected with this virus. The study included 137 (male, n 29= 101; female, n = 36; mean age, 38.7 [24–65] years) of dentists and doctors in the 30 Kanagawa Dental University Hospital. Saliva and blood samples were analyzed by PCR 31and immunochromatography for IgG and IgM, respectively. We then identified patients with saliva samples that were confirmed as PCR- and IgM-negative for COVID-19. 3233 Proportions of SARS-CoV-2 cross-reactive IgA-positive individuals were determined by 34enzyme-linked immunosorbent assay using a biotin-labeled spike S1-mFc recombinant 35protein covering the receptor-binding domain of SARS-CoV-2. The proportion of SARS-36 CoV-2 cross-reactive IgA-positive individuals was 46.7%, and this correlated negatively

with age (r = -0.218, p = 0.01). The proportion of IgA-positive individuals \geq 50 y was significantly lower than that of patients aged \leq 49 y (p = 0.008). sIgA was purified from the saliva of all patients, and the salivary sIgA was found to suppress the binding of SARS-CoV-2 spike protein to the ACE-2 receptor. We found SARS-CoV-2 cross-reactive sIgA in the saliva of some participants who had never been infected with the virus, suggesting that sIgA helps prevent SARS-CoV-2 infection.

43

44 Introduction

Secretory IgA (sIgA) prevents infections through mucosal immunity, which is an aspect 4546of the immune system. sIgA, comprising dimeric IgA, a J chain, and a secretory 47component, is secreted from glandular tissues such as salivary glands and mammary 48glands onto mucosal surfaces, where it plays a central role in preventing the entry of antigens from the mucosa [1]. Severe acute respiratory syndrome coronavirus 2 (SARS-4950CoV-2) infects humans via the oral and nasal cavities, and the lungs [2]. The squamous 51cells of the tongue and periodontal tissues express angiotensin-converting enzyme-2 52(ACE-2), a SARS-CoV-2 receptor, transmembrane protease serin 2 (TMPRSS2), and furin, 53which are proteases that promote infection [3], and saliva can harbor SARS-CoV-2 [4]. 54Saliva also contains several substances that suppress infection (such as lactoferrin,

lysozyme, and sIgA, which is the most abundant) and prevent the virus from entering
into the oral cavity [5].

57	Cross-reactive sIgA (CRsA) against SARS-CoV-2 was identified in breast milk before
58	the COVID-19 pandemic [6, 7]. Furthermore, SARS-CoV-2-reactive CD4+ T cells were
59	also detected in about 40%-60% of unexposed individuals before the pandemic,
60	suggesting that T cells have cross-reactivity to common cold coronaviruses and SARS-
61	CoV-2 [8]. Later findings [9, 10] suggested that prior infection with a coronavirus creates
62	immunological memory that is associated with sIgA cross-reactivity .
63	Infection with SARS-CoV-2 causes COVID-19, which manifests with a unique
64	spectrum of symptoms ranging from asymptomatic to fatal acute respiratory failure [11].
65	The severity and prevalence of SARS-CoV-2 infection noticeably differs among age
66	groups and countries, respectively [12]. Immune mechanisms might explain this wide
67	disparity, but they are not yet fully understood. Immunoglobulin G (IgG) can eliminate
68	SARS-CoV-2, and vaccine development against this virus is urgently needed [13].
69	However, mucosal immunity conferred by sIgA has not been investigated from the
70	viewpoints of recovery from SARS-CoV-2 infection and its prevention. New findings in
71	this area might facilitate deeper understanding of COVID-19 characteristics.
72	Therefore, we aimed to create an enzyme-linked immunosorbent assay (ELISA) for

detecting sIgA that has cross-reactivity with SARS-CoV-2, and revealed whether it has
salivary sIgA that cross-reacts with the SARS-CoV-2 spike 1 subunit for non-infected
individuals.

76

77 Methods

78 **Participant selection**

79We tested saliva and blood samples using PCR and immunochromatography, 80 respectively. Individuals with saliva samples that were confirmed by PCR and IgM 81 testing as negative for COVID-19 were included. The participants included five doctors 82and 132 dentists at the hospital attached to Kanagawa Dental University. Individuals 83 with IgA nephropathy, selective IgA deficiency, autoimmune diseases, or who had cold-84 like symptoms within the past 2 weeks were excluded. We analyzed samples from 137 (male, n = 101; female, n = 36; mean age, 38.7 [24-65] years) individuals, under the fully 8586 informed consent. This study was conducted under the approval of the Kanagawa Dental 87 University Research Ethics Review Board (Approval number: #690). This study was 88 registered in the Japanese clinical trial UMIN-CTR (Approval number: #R000046461) 89registry, which meets ICMJE standards.

90

 $\mathbf{5}$

91 Saliva collection for ELISA

92	We collected samples using Salivettes $^{\ensuremath{\mathbb{R}}}$ (Sarstedt AG & Co. KG, Nümbrecht, Germany)
93	at a fixed room of the hospital between 9 a.m. and 12 p.m. in August 2020, under the
94	infection control. The participants were instructed to refrain from eating, drinking, and
95	brushing their teeth for at least 1 hour before sample collection. The saliva samples were
96	immediately centrifuged at 2,000 × g for 15 minutes and then stored at -80°C.
97	
98	Design of ELISA for cross-reactive sIgA (CRsA) against spike
99	protein
100	We modified the ELISA system that could detect IgA cross-reactivity to influenza
101	viruses using human IgA ELISA quantitation set (#E88-102; Bethyl Laboratories,
102	Montgomery, TX, USA) reported by Yamamoto et al. [14]. Saliva samples was diluted
103	500-fold in carbonate-bicarbonate buffer and incubated for 1 hour at 25° C. Wells were
104	washed five times with wash solution. The antigen used recombinant spike 1-mFc
105	protein (#40591-V05H1; Sino Biological, Beijing, China) comprising the spike 1 subunit
106	with the spike protein receptor-binding domain (RBD) of SARS-CoV-2. The antigen was
107	labeled with biotin using a kit as described by the manufacturer (#BK01; Dojindo
108	Laboratories, Kumamoto, Japan). Biotin-labeled Spike 1 were added to a concentration

109	of 1 μ g/mL into wells and incubated for 1 hour at 25°C. Wells were washed five times
110	with wash solution. Next, streptavidin-horseradish peroxidase conjugate (SA202;
111	Millipore, USA; dilution, 1:1000) was used and reacted for 1 hour at 25° C. TMB substrate
112	solution was added for 15 mins at $25^\circ\!\mathrm{C}$ and reaction was quenched with stop solution.
113	Spike 1 protein-bound IgA was determined at 450 nm using a microplate absorbance
114	reader (Bio-Rad Laboratories, Hercules, CA, USA). Background absorbance by the
115	negative control containing PBS was subtracted from the absorbance of all saliva
116	samples.

117

118 IgA purification

119 We purified sIgA using IgA purification kits (#20395; Thermo Fisher Scientific K.K., 120Waltham, MA, USA) as described by the manufacturer, then confirmed its molecular 121weight by standard western blotting using primary anti-human IgA rabbit monoclonal 122antibodies (ab184863; Abcam Plc, Cambridge, UK) diluted 1:500 and secondary anti-123rabbit polyclonal antibodies (#P0448; Dako A/S., Glostrup, Denmark; dilution, 1:1000). 124ACE-2 binding to spike protein was inhibited by purified sIgA. We selected and 125pooled the top 20 antibody-positive, and the bottom 20 antibody-negative samples based 126on the ELISA results. The final concentrations of antibodies in the pooled positive and

127 negative saliva samples were 93.6 and 63.3 µg/mL, respectively.

128

129 Ability of sIgA antibody to inhibit ACE-2-spike protein binding

- 130 The ability of the sIgA to inhibit the binding of ACE-2 to SARS-CoV-2 spike protein
- 131 was assessed using SARS-CoV-2 spike-ACE-2 binding assay kits (#COV-SACE2-1;
- 132 RayBiotech, Peachtree Corners, GA, USA), according to the manufacturer. A SARS-CoV-
- 133 2 spike neutralizing rabbit IgG mAb (#40592-R001; Sino Biological) prepared as a
- 134 positive control and added neutralizing antibody at concentrations of 0, 0.0125, 0.025,
- 135 0.05, 0.1, and 0.2 μg/mL.
- 136

137 Questionnaire

Participants completed a self-administered questionnaire before saliva collection to
determine whether they had previously been inoculated with BCG, hepatitis B, and
influenza vaccines within the past year.

141

142 Statistical analysis

143 Negative values were set to 0 to determine relative ELISA values of CRsA, and 144 association with age was analyzed using Spearman rank correlations. Associations

145	between relative positive (> 0) and negative (0) values of CRsA in ELISA and binary
146	data, age group, gender, BCG vaccination status, hepatitis B vaccination status, and
147	influenza vaccine were examined. Associations with vaccination history were examined
148	using chi-square or Fisher exact tests. We summarized the variables of hepatitis B and
149	influenza vaccines as neither, either, or both to examine associations between the
150	number of vaccinations and IgA positivity or negativity. The variables of BCG, hepatitis
151	B vaccine, and influenza vaccine were summarized as zero, one, two, or three to examine
152	association between the number of vaccinations and IgA positivity or negativity. The
153	significance level was set to 5%. All data were statistically analyzed using SPSS version
154	26 (IBM Corp., Armonk, NY, USA).
155	

156 **Results**

157 Cross-reactive sIgA (CRsA) against spike protein

158 The relative value of CRsA determined by ELISA was set to 0 as the negative value. The

```
159 CRsA was positive in 64 (46.7%) and negative in 73 (53.3%) samples.
```



161 Fig. 1. Ratios (%) of detected cross-reactive antibodies to spike protein in saliva.

162 Cross-reactive antibodies in saliva from 137 participants were detected by ELISA. Ratios



164

165





167	Vertical axis: relative amount of IgA determined as absorbance of CRsA-positive
168	participants. Negative samples are shown as 0. The absorbance was quite high among
169	many participants aged \leq 49 years.
170	
171	Figure 2 showed associations between age and cross-reactive IgA. Age significantly
172	and negatively correlated with relative CRsA (r = -0.218, p = 0.01). The positive rate of
173	CRsA was significantly lower in participants aged $\geq 50,$ compared with those aged ≤ 49
174	years (p = 0.008). The association between vaccines and CRsA positivity or negativity
175	was not significant.

176

Variables		Total	IgA-positive		n *
		n	n	%	þ
Age (y)	20-29	32	19	59.4	0.081
	30-39	54	27	50.0	
	40-49	23	11	47.8	
	50-59	20	4	20.0	
	<u>></u> 60	8	3	37.5	
	20-49	109	57	52.3	0.008
	<u>></u> 50	28	7	25.0	
Sex	Male	101	48	47.5	0.452
	Female	36	16	44.4	
Vaccination					
BCG	Yes	102	49	48.0	0.781
	No	8	4	50.0	

177 Table 1. Associations between age, sex, and vaccination and CRsA positivity.

	Unknown	27	11	40.7	
Hepatitis B	Yes	124	58	46.8	0.992
	No	11	5	45.5	
	Unknown	2	1	50.0	
Influenza	Yes	127	60	47.2	0.458
	No	10	4	40.0	
Hepatitis B	Neither	1	1	100.0	0.114
and Influenza	Either	19	7	36.8	
	Both	115	55	47.8	
BCG,	One	3	1	33.3	0.809
Hepatitis B and	Two	21	11	52.4	
Influenza	Three	84	40	47.6	

178 *Chi-square or Fisher exact tests.

179

180 CRsA inhibition tests

181 Western blots revealed purified IgA as a single band of ~ 60 kDa, confirming that the

182 protein was sIgA (data not shown).

In the positive control, the range of absorbance from the addition of spike neutralizing antibody at different concentrations (0–0.2 μ g/mL) was 2.155–0.493, with the concentration-dependent decrease confirming neutralizing activity. The neutralizing antibody against the spike protein showed an absorbance of 2.155 at an antibody concentration of 0 μ g/mL. This absorbance indicates the absorbance when ACE-2 and the spike protein are most bound by ELISA. Since the CRsA-negative saliva sample showed an absorbance of 2.402, which was 2.155 or higher, the binding between ACE-2

and the spike protein was not inhibited. The CRsA-positive saliva sample had an
absorbance of 1.678, and the binding between ACE-2 and spike protein was partially
inhibited.

193

194 **Discussion**

195This study found that 46.7% of saliva samples from 137 participants contained CRsA 196against SARS-CoV-2 spike 1. The spike 1 region that we examined included the RBD 197 that binds the SARS-CoV-2 receptor ACE-2. This region is important for preventing 198 infections and could thus be a target for vaccine development [14]. A previous ELISA of 199SARS-CoV-2 CRsA in breast milk found positivity rates of 100% and 80%, respectively, 200with the total spike protein and RBD as the antigen [6]. However, the salivary values in 201the present study were lower than both of these. This might be because more sIgA is 202produced in breast milk than in saliva [15]. The abundance of CRsA in breast milk is a 203proven post-vaccination response [16], which could explain why the CRsA positivity rate 204 was lower in saliva than breast milk. 205Participants with saliva samples that tested negative for COVID-19 determined by 206PCR and antibody tests did not develop COVID-19 at the time of this article submission.

207 $\,$ Thus, we believe that they had not been exposed to SARS-CoV-2. As such, we revealed

208	sIgA antibodies against the spike 1 protein of SARS-CoV-2 in individuals with no history
209	of SARS-CoV-2 infection. Only one other study found salivary IgA antibodies that cross-
210	react with the spike protein of SARS-CoV-2 before the COVID-19 pandemic [17]. The
211	nucleocapsid proteins of coronaviruses are highly homologous, but their spike proteins
212	share little commonality [18]. Patients with a history of infection with HCoV-OC43 and
213	other coronaviruses have antibodies against SARS-CoV-1 and antibodies that cross-react
214	to the SARS-CoV nucleocapsid protein, respectively [19]. Furthermore, whereas HCoV-
215	NL63 uses ACE-2 as a receptor, its spike protein shares little homology with SARS-CoV-
216	2 [20]. However, cross-reactivity of the receptor-binding motif 3 of NL63 and COV2-
217	SPIKE $_{421-434}$ of SARS-CoV-2 has recently been reported [20]. As past common
218	coronavirus infection can induce antibodies that are cross-reactive to spike and
219	nucleocapsid proteins, it is reasonable that saliva contains antibodies such as salivary
220	sIgA with cross-reactivity to SARS-CoV-2. However, the epitope behind salivary CRsA
221	cross-reactivity remains to be clarified.
222	The present study found that CRsA levels decreased with advancing age. This might

be explained by the fact that IgA levels decrease with age [21]. In addition, cross-reactive IgG antibodies were identified in 62%, 43.75%, and 5.72% of serum samples from individuals aged 1–16, 17–25, and \geq 26 years, respectively, before the SARS-CoV-2

226	pandemic [9]. Because children are infected with common coronaviruses more frequently,
227	this seems to indicate that that more exposure leads to more individuals with cross-
228	reactive antibodies. Moreover, cross-reactive T cells for SARS-CoV-2 are rare in elderly
229	persons [22]. These results can explain why CRsA is prevalent in young persons but
230	uncommon in older persons. The mechanism behind the fact that COVID-19 is less
231	frequently severe and often asymptomatic in children [23] and adolescents [12] might be
232	partially explained.
233	We showed here that the binding between ACE-2 and spike protein was not inhibited
234	in individuals without CRsA. In contrast, because cross-reactive IgA inhibited the
235	binding of ACE-2 to spike protein, salivary CRsA might prevent SARS-CoV-2 infection
236	via a neutralization reaction, because IgA functions as a neutralizing antibody against
237	SARS-CoV-2 [24]. Although saliva contains SARS-CoV-2, it also contains infection
238	inhibitory factors [3]. Saliva lactoferrin is an infection suppressor that binds to SARS-
239	CoV-2 [25]. Because sIgA has an antigen-processing function that is synergistic with
240	lactoferrin, lysozyme, and peroxidase, salivary anti-bacterial or anti-viral factors might
241	enhance the action of CRsA [26].
242	Early SARS-CoV-2 specific humoral responses are dominated by IgA antibodies,

243 indicating that these play an important role in immunity after SARS-CoV-2 infection

244	[27]. On the other hand, neutralizing IgA antibodies against SARS-CoV-2 persist in
245	saliva for 49 to 73 days after symptoms appear [27]. Spike 1-CRsA in saliva is also
246	associated with the severity of pneumonia in COVID-19 [17]. Saliva can be collected
247	easily and noninvasively, and sIgA is a practical test specimen because it is resistant to
248	degradation and does not have strict transport conditions. Developing a method to easily
249	and non-invasively measure sIgA in saliva might be important for the diagnosis or risk
250	prediction of SARS-CoV-2 infection and responses to vaccines in the future.
251	One limitation of the present study was the low number of participants. Although
252	vaccines stimulate the production of cross-reactive antibodies [7], we found no significant
253	association between vaccines and cross-reactive antibodies. Future investigations should
254	compare individuals who are not involved in medical care (without experience of
255	vaccination).

256

257 Conclusions

This study identified the SARS-CoV-2 cross-reactive IgA spike protein in saliva from individuals who have not experienced COVID-19. Elderly persons showed lower levels of SARS-CoV-2 spike protein-CRsA than adolescents. Salivary IgA might block the binding of ACE-2 to the spike protein. We revealed the importance of IgA as an inhibitor of SARS-

262	CoV-2 infection in the oral cavity. Our findings are novel, as few studies have examined
263	anti-SARS-CoV-2 antibodies in this compartment, despite the fact of the oral cavity being
264	a viral replication site [28].
265	
266	Acknowledgments
267	We are grateful to Ms. Makiko Yamada at the Central Research Support Center of

268 Kanagawa Dental University Graduate School for providing valuable technical269 assistance.

270

271 Author contributions

- 272 **Conceptualization**: Keiichi Tsukinoki.
- 273 Data analysis: Tatsuo Yamamoto.
- 274 **Sample collection**: Keisuke Handa, Mariko Iwamiya.
- 275 Investigation: Juri Saruta.
- 276 **Project administration**: Satoshi Ino.
- 277 Supervision: Takashi Sakurai.
- 278 **Funding acquisition**: Isamu Kashima.
- 279 Writing-original draft: Keiichi Tsukinoki.

280 Writing-review: Tatsuo Yamamoto, Keisuke Handa, Juri Saruta.

281

282	Referen	ces

- 283 1. Yamamoto Y, To M, Hayashi T, Shimizu T, Kamata Y, Saruta J, et al. Intake of
- 284 indigestible carbohydrates influences IgA response and polymeric Ig receptor
- expression in the rat submandibular gland. Brit J Nutri. 2015;113: 1859-1902.
- 286 2. Shi Y, Wang G, Cai X, Deng JW, Zheng L, Zhu HH, et al. An overview of COVID-19. J
- 287 Zhejiang Univ Sci B. 2020;21: 343-360. doi: 10.1631/jzus.B2000083.
- 288 3. Sakaguchi W, Kubota N, Shimizu T, Saruta J, Fuchida S, Kawata A, et al. Existence
- of SARS CoV 2 entry molecules in the oral cavity. Int J Mol Sci. 2020;21(17):
- 290 6000. doi: 10.3390/ijms21176000.
- 4. Xu R, Cui B, Duan X, Zhang P, Zhou X, Yuan Q. Saliva: potential diagnostic value
- 292 and transmission of 2019-nCoV. Int J Oral Sci. 2020;12: 11. doi: 10.1038/s41368-020-

293 0080-z.

- 294 5. Hayashi T, To M, Saruta J, Sato C, Yamamoto Y, Kondo Y, et al. Salivary lactoferrin
- 295 is transferred into the brain via the sublingual route. Biosci Biotechnol
- 296Biochem. 2017;81: 1300-1304. doi: 10.1080/09168451.2017.1308241.
- 297 6. Fox A, Marino J, Amanat F, Krammer F, Hahn-Holbrook J, Zolla-Pazner S, et al.

298	Robust	and	specific	secretory	IgA	against	SARS-CoV-2	detected	ın	human	milk.

299 iScience. 2020;23(11): 101735. doi: 10.1016/j.isci.2020.101735.

- 300 7. Veronique DM, Dung MD, Gabrielle BM, David AS, Antti S, Kirsi MJ, et al.
- 301 Difference in levels of SARS-CoV-2 S1 and S2 subunits- and nucleocapsid protein-
- 302 reactive SIgM/IgM, IgG and SIgA/IgA antibodies in human milk. J Perinatol. 2020;1:
- 303 1-10. doi: 10.1038/s41372-020-00805-w.
- 304 8. Grifoni A, Weiskopf D, Ramirez SI, Mateus J Dan JM, Moderbacher CR, et al. Target
- 305 of T cell responses SARS-CoV-2 coronavirus in humans with COVID-19 disease and
- 306 unexposed individuals. Cell. 2020;181: 1489-1501.
- 307 9. Ng KW, Faulkner N, Cornish GH, Rosa A, Harvey R, Hussain S, et al. Preexisting
- and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020;370: 13391343.
- 310 10. Zhang J, Wu Q, Liu Z, Wang Q, Wu J, Hu Y, et al. Spike-specific circulating T
- 311 follicular helper cell and cross-neutralizing antibody responses in COVID-19-
- 312 convalescent individuals. Nat Microbiol. 2021;6(1): 51-58. doi: 10.1038/s41564-020313 00824-5.
- 314 11. Tyrpsteen W, Cleemput JV, van Snippenberg W, Gerio S, Vandekehove L. On the
 315 whereabouts of SARS-CoV-2 in the human body: A systematic review.

316 PLoS Pathog. 2020;16(10): e1009037.

- 317 12. Watanabe S, Naito Y, Yamamoto T. Host factors that aggravate COVID-19
- 318 pneumonia. Int J Family Med Primary Care. 2020;1(3): 1-4.
- 319 13. Yamamoto Y, Saruta J, Takahashi T, To M, Shimizu T, Hayashi T, et al. Effect of
- 320 ingesting yogurt fermented with Lactobacillus delbrueckii ssp. bulgaricus
- 321 OLL1073R-1 on influenza virus-bound salivary IgA in elderly residents of nursing
- homes: a randomized control trial. Acta Odont Scand. 2019;77(7): 517-524.
- 323 14. Ejemel M, Li Q, Hou S, Schiller ZA, Tree JA, Wallace A, et al. A cross-reactive human
- 324 IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction. Nat Commun.
- 325 2020;11: 4198. doi: 10.1038/s41467-020-18058-8.
- 326 15. Brandtzaeg P. The secretory immune system of lactating human mammary glands
- 327 compared with other exocrine organs. Ann N Y Acad Sci. 1983;30(409): 353-382.
- 328 16. Jertborn M, Svennerholm AM, Holmgren J. Saliva, breast milk, and serum antibody
- 329 responses as indirect measures of intestinal immunity after oral cholera vaccination
- of natural disease. J Clin Microbiol. 1986;24(2): 203-209.
- 331 17. Varadhachary A, Chatterjee D, Garza J, Garr RP, Foley C, Letkeman A, et al.
- 332 Salivary anti-SARS-CoV-2 IgA as an accessible biomarker of mucosal immunity
- 333 against COVID-19. medRxiv. 2020;2020.08.07.20170258. doi:

334 10.1101/2020.08.07.20170258.

335	18. Kang S,	Yang M,	Hong Z,	Zhang L,	Huang Z,	Chen X, et al	. Crystal structure o	of
-----	-------------	---------	---------	----------	----------	---------------	-----------------------	----

- 336 SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique
- drug targeting sites. BioRxiv. doi: https://doi.org/10.1101/2020.03.06.977876.
- 338 19. Patrick D, Petric M, Skowronski DM, Guasparini R, Booth TF, Krajden M, et al. An
- 339 outbreak of human coronavirus OC43 infection and serological cross-reactivity with
- 340 SARS coronavirus. Can J Infect Dis Med Microbiol. 2006;17(6): 330-336. doi:
- 341
 0.1155/2006/152612.
- 342 20. Simula ER, Manca MA, Jasemi S, Uzzau S, Rubino S, Manchia P, et al. HCoV-NL63
- 343 and SARS-CoV-2 share recognized epitopes by the humoral response in sera of
- 344 people collected pre- and during CoV-2 pandemic. Microorganisms. 2020;8(12):
- 345 1993. doi: 10.3390/microorganizms8121993.
- 346 21. Tanida T, Ueta E, Tobiume A, Hamada T, Rao F, Osaki T. Influence of aging on
- 347 candida growth and adhesion regulatory agents in saliva. J Oral Pathol Med.
- 348 2001;30: 328-335.
- 22. Saletti G, Gerlach T, Jansen JM, Molle A, Elbahesh H, Ludlow M, et al. Older
- adults lack SARS CoV-2 cross-reactive T lymphocyte directed to human OC43 and
- 351 NL63. Scientific Rep. 2020;10: 21447.

21

352	23.	Tosif S, Neeland MR, Sutton P, Licciardi P, Sarkar S, Selva KJ, et al. Immune
353		responses to SARS-CoV-2 in three children of parents with symptomatic COVID-
354		19. Nat Commun. 2020;11: 5703.
355	24.	Wang C, Li W, Dubravka D, Okabe NMA, van Haperen R, Osterhaus ADME, et al.
356		A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun.
357		2020;11: 2251.
358	25.	Hu Y, Meng X, Zhang F, Xiang Y, Wang J. The in vitro antiviral activity of
359		lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by
360		targeting the heparan sulfate co-receptor. Emerg Microbes Infect. 2021;10(1): 317-
361		330.
362	26.	Rudney JD, Smith QT. Relationship between levels of lysozyme, lactoferrin,
363		salivary peroxidase and secretory immunoglobulin A in stimulated parotid saliva.
364		Infect Immun. 1985;49: 469-475.
365	27.	Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Clear L, et al. IgA dominates the
366		early neutralizing antibody response to SARS-CoV-2. Sci Transl Med. 2020;13(577):
367		eabd2223. doi: 10.1126/scitranslmed.abd2223.

22

- 368 28. Isho B, Abe KT, Zuo M, Jamal A, Rathod B, Wang JH, et al. Persistence of serum
- 369 and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients.
- 370 Sci Immunol. 2020;5(52): eabe5511. doi: 10.1126/sciimmunol.abe5511.